In the present study, we have shown, to the best of our knowledge, for the first time, 100 % DFS for patients having tumours characterized by low topoisomerase IIα expression and high microvessel density and BCL-2 positivity (all assessed by immunohistochemistry). The gene discussed is BCL2; the disease is neoplasm.